Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 13770
Country/Region: Ethiopia
Year: 2015
Main Partner: Harari Regional Health Bureau
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $1,322,998 Additional Pipeline Funding: $25,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $90,000
Care: TB/HIV (HVTB) $100,000
Care: Pediatric Care and Support (PDCS) $20,000
Laboratory Infrastructure (HLAB) $40,000
Strategic Information (HVSI) $24,000
Health Systems Strengthening (OHSS) $43,000
Biomedical Prevention: Blood Safety (HMBL) $15,000
Biomedical Prevention: Injection Safety (HMIN) $0
Testing: HIV Testing and Counseling (HVCT) $45,000
Sexual Prevention: Other Sexual Prevention (HVOP) $30,571
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $60,000
Treatment: Adult Treatment (HTXS) $820,427
Treatment: Pediatric Treatment (PDTX) $35,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 4,300
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 426
FN_THER Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2016 122
FN_THER Number of PLHIV who were nutritionally assessed and found to be clinically undernourished 2016 367
HTS_TST By Test Result: Negative 2016 52,332
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 53,152
HTS_TST Sum of Test Result disaggregates 2016 53,152
HTS_TST_POS By Test Result: Positive 2016 820
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2016 6
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2016 84
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 73
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 69
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 45
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 24
PMTCT_ARV Sum of New and Current disaggregates 2016 69
PMTCT_EID By infants who received a virologic test within 2 months of birth 2016 53
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 13
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 66
PMTCT_EID Sum of Infant Age disaggregates 2016 66
PMTCT_STAT By: Known positives at entry 2016 52
PMTCT_STAT By: Number of new positives identified 2016 22
PMTCT_STAT Number of new ANC and L&D clients 2016 4,476
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 4,252
PMTCT_STAT Sum of Positives Status disaggregates 2016 74
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2016 83
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 83
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 4,300
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 4,450
TX_CURR Age/Sex: <1 Female 2016 3
TX_CURR Age/Sex: <1 Male 2016 5
TX_CURR Age/Sex: 1-4 Female 2016 14
TX_CURR Age/Sex: 1-4 Male 2016 17
TX_CURR Age/Sex: 5-14 Female 2016 32
TX_CURR Age/Sex: 5-14 Male 2016 29
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 1,871
TX_CURR Sum of age/sex disaggregates 2016 1,871
TX_NEW By Age/Sex: <1 Female 2016 1
TX_NEW By Age/Sex: <1 Male 2016 1
TX_NEW By Age/Sex: 1-4 Female 2016 4
TX_NEW By Age/Sex: 1-4 Male 2016 7
TX_NEW By Age/Sex: 10-14 Female 2016 2
TX_NEW By Age/Sex: 10-14 Male 2016 2
TX_NEW By Age/Sex: 15-19 Female 2016 5
TX_NEW By Age/Sex: 15-19 Male 2016 1
TX_NEW By Age/Sex: 20-24 Female 2016 32
TX_NEW By Age/Sex: 20-24 Male 2016 4
TX_NEW By Age/Sex: 25-49 Female 2016 121
TX_NEW By Age/Sex: 25-49 Male 2016 70
TX_NEW By Age/Sex: 5-9 Female 2016 5
TX_NEW By Age/Sex: 5-9 Male 2016 5
TX_NEW By Age/Sex: 50+ Female 2016 3
TX_NEW By Age/Sex: 50+ Male 2016 9
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 272
TX_NEW Sum of Age/Sex disaggregates 2016 272
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 255
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 300
Cross Cutting Budget Categories and Known Amounts Total: $272,953
Condoms: Policy, Tools, and Services $6,739
Key Populations: Sex Workers $13,479
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Water $6,739
Gender: Gender Based Violence (GBV) $6,739
Post GBV Care
Implementation
Capacity building
Education $13,479
Human Resources for Health $134,799
Food and Nutrition: Policy, Tools, and Service Delivery $13,479
Renovation $52,500
Motor Vehicles: Purchased $25,000